Bispecific antibody platforms for cancer immunotherapy

被引：65

作者：

Lameris, Roeland ^{[1
]}

de Bruin, Renee C. G. ^{[1
]}

Schneiders, Famke L. ^{[1
]}

Henegouwen, Paul M. P. van Bergen en ^{[2
]}

Verheul, Henk M. W. ^{[1
]}

de Gruijl, Tanja D. ^{[1
]}

van der Vliet, Hans J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands

[2] Univ Utrecht, Fac Sci, Dept Biol, Div Cell Biol, NL-3584 CH Utrecht, Netherlands

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2014年 / 92卷 / 03期

关键词：

Bi-specific antibodies; Dual specific retargeting; Immune effector cells; Anti-cancer therapy; NATURAL-KILLER-CELLS; DELTA T-CELLS; SINGLE-CHAIN ANTIBODY; EPCAM X ANTI-CD3; ACUTE LYMPHOBLASTIC-LEUKEMIA; EXPRESSING TUMOR-CELLS; NKT CELLS; MALIGNANT ASCITES; ANTITUMOR-ACTIVITY; PROSTATE-CANCER;

D O I：

10.1016/j.critrevonc.2014.08.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past decades advances in bioengineering and expanded insight in tumor immunology have resulted in the emergence of novel bispecific antibody (bsAb) constructs that are capable of redirecting immune effector cells to the tumor microenvironment. (Pre-) clinical studies of various bsAb constructs have shown impressive results in terms of immune effector cell retargeting, target dependent activation and the induction of anti-tumor responses. This review summarizes recent advances in the field of bsAb-therapy and limitations that were encountered. Furthermore, we will discuss potential future developments that can be expected to take the bsAb approach successfully forward. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：153 / 165

页数：13

共 120 条

[11] Generation and characterization of monospecific and bispecific hexavalent trimerbodies [J].

Blanco-Toribio, Ana ;

Sainz-Pastor, Noelia ;

Alvarez-Cienfuegos, Ana ;

Merino, Nekane ;

Cuesta, Angel M. ;

Sanchez-Martin, David ;

Bonet, Jaume ;

Santos-Valle, Patricia ;

Sanz, Laura ;

Oliva, Baldo ;

Blanco, Francisco J. ;

Alvarez-Vallina, Luis .

MABS, 2013, 5 (01) :70-79

[12] Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside [J].

Braza, Mounia S. ;

Klein, Bernard .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (02) :123-132

[13] MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors [J].

Brischwein, K ;

Schlereth, B ;

Guller, B ;

Steiger, C ;

Wolf, A ;

Lutterbuese, R ;

Offner, S ;

Locher, M ;

Urbig, T ;

Raum, T ;

Kleindienst, P ;

Wimberger, P ;

Kimmig, R ;

Fichtner, I ;

Kufer, P ;

Hofmeister, R ;

da Silva, AJ ;

Baeuerle, PA .

MOLECULAR IMMUNOLOGY, 2006, 43 (08) :1129-1143

[14] A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells [J].

Buehler, P. ;

Wolf, P. ;

Gierschner, D. ;

Schaber, I. ;

Katzenwadel, A. ;

Schultze-Seemann, W. ;

Wetterauer, U. ;

Tacke, M. ;

Swamy, M. ;

Schamel, W. W. A. ;

Elsaesser-Beile, U. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (01) :43-52

[15] Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion [J].

Buhmann, R. ;

Simoes, B. ;

Stanglmaier, M. ;

Yang, T. ;

Faltin, M. ;

Bund, D. ;

Lindhofer, H. ;

Kolb, H-J .

BONE MARROW TRANSPLANTATION, 2009, 43 (05) :383-397

[16] Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study [J].

Burges, Alexander ;

Wimberger, Pauline ;

Kuemper, Carolin ;

Gorbounova, Vera ;

Sommer, Harald ;

Schmalfeldt, Barbara ;

Pfisterer, Jacobus ;

Lichinitser, Michail ;

Makhson, Anatoliy ;

Moiseyenko, Vladimir ;

Lahr, Angelika ;

Schulze, Elisabeth ;

Jaeger, Michael ;

Stroehlein, Michael A. ;

Heiss, Markus Maria ;

Gottwald, Thomas ;

Lindhofer, Horst ;

Kimmig, Rainer .

CLINICAL CANCER RESEARCH, 2007, 13 (13) :3899-3905

[17] Bispecific antibodies for cancer therapy The light at the end of the tunnel? [J].

Chames, Patrick ;

Baty, Daniel .

MABS, 2009, 1 (06) :539-547

[18] Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients [J].

Chang, DH ;

Osman, K ;

Connolly, J ;

Kukreja, A ;

Krasovsky, J ;

Pack, M ;

Hutchinson, A ;

Geller, M ;

Liu, N ;

Annable, R ;

Shay, J ;

Kirchhoff, K ;

Nishi, N ;

Ando, Y ;

Hayashi, K ;

Hassoun, H ;

Steinman, RM ;

Dhodapkar, MV .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (09) :1503-1517

[19] NK cell-based immunotherapy for malignant diseases [J].

Cheng, Min ;

Chen, Yongyan ;

Xiao, Weihua ;

Sun, Rui ;

Tian, Zhigang .

CELLULAR & MOLECULAR IMMUNOLOGY, 2013, 10 (03) :230-252

[20] Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma [J].

Choi, Bryan D. ;

Kuan, Chien-Tsun ;

Cai, Mingqing ;

Archer, Gary E. ;

Mitchell, Duane A. ;

Gedeon, Patrick C. ;

Sanchez-Perez, Luis ;

Pastan, Ira ;

Bigner, Darell D. ;

Sampson, John H. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (01) :270-275

← 1 2 3 4 5 6 7 8 9 10 →